Knowthestock.com
AKRX - Akorn, Inc.

Sell

Weak GrowthEarnings/Profit is Negative

7%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 0.09%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -54.01%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 0.49
Debt Ratio is 1.08
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 1.71
Cash Flow
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Akorn, Inc. (AKRX) - http://www.akorn.com
Akorn, Inc. engages in the development, manufacture, and marketing of generic and prescription pharmaceuticals, and animal and consumer health products. It operates through the Prescription Pharmaceuticals and Consumer Health business segments. The Prescription Pharmaceuticals segment manufactures and markets generic and branded prescription pharmaceuticals including ophthalmic, injectable, oral liquids, topical, inhalants, and nasal sprays. The Consumer Health segment offers branded and private-label animal health; and over-the-counter products. The company was founded in 1971 and is headquartered in Lake Forest, IL.
Exchange - NASDAQ
Industry - Pharmaceuticals: Major
Sector - Health Technology
CEO - Douglas S. Boothe
Employees - 2,227
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.